<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019327</url>
  </required_header>
  <id_info>
    <org_study_id>19-041</org_study_id>
    <nct_id>NCT04019327</nct_id>
  </id_info>
  <brief_title>A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer</brief_title>
  <official_title>A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects With Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine what the safest dose of talazoparib plus&#xD;
      temozolomide for participants with metastatic castration resistant prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])</measure>
    <time_frame>30 days after last dose of study treatment (+/- 3 days)</time_frame>
    <description>Toxicities will be classified by severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5 (NCI CTCAE v5.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Overall Response Rate</measure>
    <time_frame>30 days after last dose of study treatment (+/- 3 days)</time_frame>
    <description>Overall best response rate (confirmed CT or PR) will be calculated according to RECIST v1.1</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Prostate Neoplasm</condition>
  <condition>Prostate Cancer Metastatic</condition>
  <condition>Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Metastatic Castration Resistant Prostate Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants have Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib</intervention_name>
    <description>Phase I maximum tolerated dose portion:&#xD;
Level 1, 2, 3 - 1 mg QD Days 1-6 Level 4, 5 - 1.25 mg QD Days 1-6 Level 6 - 1.5 mg QD Days 1-6</description>
    <arm_group_label>Metastatic Castration Resistant Prostate Cancer</arm_group_label>
    <other_name>Tala</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Phase I maximum tolerated dose portion:&#xD;
Level 1 - 37.5 mg/m2 QD Days 2-8 Level 2 - 75 mg/m2 QD Days 2-8 Level 3 &amp; 4 - 100 mg/m2 QD Days 2-8 Level 5 &amp; 6 - 125 mg/m2 QD Days 2-8</description>
    <arm_group_label>Metastatic Castration Resistant Prostate Cancer</arm_group_label>
    <other_name>TMZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent and HIPAA authorization for the&#xD;
             release of personal health information or have their legally authorized representative&#xD;
             provide written informed consent. A signed informed consent must be obtained prior to&#xD;
             performing screening procedures.&#xD;
&#xD;
        NOTE: HIPAA authorization may be either included in the informed consent or obtained&#xD;
        separately&#xD;
&#xD;
          -  Males 18 years of age or above&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Bilateral orchiectomy or ongoing androgen deprivation therapy with a GnRH&#xD;
             agonist/antagonist (surgical or medical castration)&#xD;
&#xD;
          -  Progression of mCRPC on treatment with at least 1 second generation hormonal agent&#xD;
             (e.g., enzalutamide and/or abirateroneacetate/prednisone)&#xD;
&#xD;
          -  Documented progressive mCRPC based on at least one of the following criteria:&#xD;
&#xD;
               -  PSA progression defined as at least 2 rises in PSA with a minimum of a 1-week&#xD;
                  interval&#xD;
&#xD;
               -  1.0 ng/mL is the minimal starting value if confirmed rise is only indication of&#xD;
                  progression&#xD;
&#xD;
               -  Soft-tissue progression per RECISTv1.1&#xD;
&#xD;
               -  Progression of bone disease (evaluable disease) or tow or more new bone lesions&#xD;
                  by bone scan&#xD;
&#xD;
          -  Metastatic disease documented by bone lesions on whole-body radionuclide bone scan or&#xD;
             soft tissue disease y computed tomography/magnetic-resonance imaging (CT/MRI).&#xD;
&#xD;
          -  Consent to a fresh tumor biopsy during screening or have sufficient archival tumor&#xD;
             tissue available for molecular profile and biomarker analyses&#xD;
&#xD;
          -  ECOG status of 0 or 1 (Appendix A: Performance Status Criteria)&#xD;
&#xD;
          -  Serum testosterone &lt;/= 50mg/dL at screening&#xD;
&#xD;
          -  Adequate organ function with acceptable initial laboratory values within 14 days of&#xD;
             treatment start:&#xD;
&#xD;
        Absolute neutrophil count (ANC): &gt;/= 1,500/ul Hemoglobin: &gt;/= 9g/dL Platelet count: &gt;/=&#xD;
        100,00/ul Creatinine: &gt;/= 60 mL/min estimated using the Cockcroft-Gault equation Potassium:&#xD;
        &gt;/= 3.5 mmol/L (within institutional normal range) Bilirubin: &lt;/= 1.5 ULN (unless&#xD;
        documented Gilbert's disease) SGOT(AST): &lt;/= 2.5 x ULN SGPT (ALT): &lt;/= 2.5 x ULN&#xD;
&#xD;
          -  Subjects must agree to use a highly effective method of contraception (e.g.,&#xD;
             spermicide in conjunction with a barrier such as a condom) or sexual abstinence during&#xD;
             treatment, and for at least 7 months after completing therapy. Furthermore, male&#xD;
             patients with female partners of reproductive potential and pregnant partners must use&#xD;
             a condom (even after vasectomy), during treatment and for at least 4 months after the&#xD;
             final dose. Sperm donation is prohibited during the study and for 30 days after the&#xD;
             last dose of study drug. Female partners must use hormonal or barrio contraception&#xD;
             unless postmenopausal or abstinent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with a taxane-based chemotherapy for mCRPC (prior treatment with a&#xD;
             taxane-based chemotherapy for metastatic non-castrate prostate cancer is permitted)&#xD;
&#xD;
          -  Prior treatment with a PARP inhibitor, platinum, cyclophosphamide, mitozantrone&#xD;
             chemotherapy, ortemozolmide&#xD;
&#xD;
          -  Subject has received radiation therapy within 3 weeks (within 2 weeks, if single&#xD;
             fraction of radiotherapy) of treatment start&#xD;
&#xD;
          -  Documented carrier of a pathogenic or likely pathogenic germline or somatic mutation&#xD;
             in BRCA 1, BRC 2 or ATM or known carrier (pathogenic or likely pathogenic) or one of&#xD;
             the following DNA Damage Repair genes considered as sensitizing tumors to PARP&#xD;
             inhibitors: FANCA, CHECK2, PALB2, MRE11A, NBN, RAD51C, ATR, MLH1, and CDK12. Testing&#xD;
             is required for BRCA 1, BRCA 1, or ATM. If a subject has had next generation&#xD;
             sequencing that did not include FANCA, CHECK2, PALB2, MRE11A, NBN, RAD51C, ATR, MLH1,&#xD;
             or CDK12 he will not be excluded from the study if status is unknown.&#xD;
&#xD;
        Note, if testing is germline negative, somatic testing is still required. If the subject is&#xD;
        germline positive, the subject in ineligible.&#xD;
&#xD;
          -  Use of systemic hormonal (except for GnRH analog), biologic, radium-223, or any&#xD;
             investigational therapy for treatment of metastatic prostate cancer within 4 weeks&#xD;
             prior to treatment start. Exceptions include abiraterone, which may not have been&#xD;
             administered within 2 weeks of treatment start.&#xD;
&#xD;
          -  Medical conditions such as uncontrolled hypertension, uncontrolled diabetes mellitus,&#xD;
             or cardiac disease that would, in the opinion of the investigator, make this protocol&#xD;
             unreasonably hazardous to the subject.&#xD;
&#xD;
          -  Known or suspected brain metastasis or active leptomeningeal disease.&#xD;
&#xD;
          -  Symptomatic or impending spinal cord compression or cauda equine syndrome&#xD;
&#xD;
          -  Diagnosis of myelodysplastic syndrome (MDS)&#xD;
&#xD;
          -  History of another cancer within 2 years of treatment start with the exception of&#xD;
             nonmelanoma skin cancers or American Joint Committee on Cancer stage 0 or stage 1&#xD;
             cancer that has a remote probability of recurrence in the opinion of the investigator&#xD;
             and the Sponsor&#xD;
&#xD;
          -  Use of any prohibited concomitant medications (Appendix C: Medications With the&#xD;
             Potential for Drug-Drug Interactions) within 14 days prior to the first dose of&#xD;
             talazoparib&#xD;
&#xD;
          -  Grade &gt; 2 treatment-related toxicity unresolved from prior therapy&#xD;
&#xD;
          -  Known allergy to any of the compounds under investigation&#xD;
&#xD;
          -  Any other condition which, in the opinion of the investigator, would preclude&#xD;
             participation in this trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Autio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Autio, MD</last_name>
    <phone>646-422-4632</phone>
    <email>AutioK@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Howard Scher, MD</last_name>
    <phone>646-888-4878</phone>
    <email>scherh@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Autio, MD</last_name>
      <phone>646-422-4632</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Limited Protocol Activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Autio, MD</last_name>
      <phone>646-422-4632</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (Limited protocol activity)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Autio, MD</last_name>
      <phone>646-422-4632</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (Limited Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Autio, MD</last_name>
      <phone>646-422-4632</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Autio, MD</last_name>
      <phone>646-422-4632</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Limited Protocol Activities)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Autio, MD</last_name>
      <phone>646-422-4632</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Devitt, MD</last_name>
      <phone>434-924-9333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christos Kyriakopoulos, MD</last_name>
      <phone>608-263-0786</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>talazoparib</keyword>
  <keyword>temozolomide</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>19-041</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>• Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

